

# Drug approved by FDA can increase walking speed for people with MS

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for AMPYRA™ (dalfampridine), an oral treatment to improve walking speed in patients with multiple sclerosis

(MS).

AMPYRA demonstrated efficacy in people with all four major types of MS (relapsing remitting, secondary progressive, progressive relapsing and primary progressive).

AMPYRA can be used alone or with existing MS therapies,

“Before Ampyra, my walking was very, very slow. People would come to the door, ring the doorbell and I wouldn't get there in time to answer the door before they left. If the dog had to go out I often couldn't get him out in time. But it was amazing the difference in what I could do after getting on Ampyra that I couldn't do before — at least in a timely fashion. So, being able to do something more quickly has made a huge difference.

“Before Ampyra, my walking was definitely slowing down. It caused various and sundry problems because it kept getting slower, but maybe only do one instead of three or four. After I got on Ampyra, I could walk more quickly.

“I noticed when I first got MS, my walking kept getting slower. To get to the front door in time to answer it before somebody went away, I couldn't. The increased speed is a tremendous help.”

*Jackie Havener, MS patient*

uld  
time  
often  
e in  
efore  
y more



slower. Not only did I have to decide which errands I would go  
on Ampyra, the walking ability was faster and I could do things  
er. Once I got on Ampyra, it started improving. I could get to the  
could answer the telephone before my machine got it. So having

including immunomodulator drugs.

Ron Cohen, M.D., President and CEO of Acorda Therapeutics, said, "... We thank all of the clinicians, people living with MS and medical and patient support organizations who joined in this effort over the past decade...."

AMPYRA, which was previously referred to as Fampridine-SR, is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP), which was previously called fampridine.

AMPYRA is administered as a 10 mg tablet twice daily, approximately 12 hours apart. During a treatment period, a significantly greater proportion of patients taking AMPYRA 10 mg twice daily had increases in walking speed of at least 10%, 20%, or 30% compared to those getting a placebo.

Acorda expects AMPYRA to be commercially available in the United States in March 2010. AMPYRA will be distrib-

uted exclusively through a network of specialty pharmacies and coordinated by AMPYRA patient support services.

Customer care agents will be available to help healthcare professionals process prescriptions, work with insurance carriers to facilitate coverage, and help patients to access benefits available through reimbursement programs.

AMPYRA Patient Support Services-888-881-1918 for more information.

**Important safety information**  
AMPYRA can cause seizures; the risk of seizures increases with increasing AMPYRA doses. AMPYRA is contraindicated in patients with a prior history of seizure. Discontinue AMPYRA use if seizure occurs.

AMPYRA is contraindicated in patients with moderate to severe renal impairment ( $CrCl \leq 50$  mL/min); the risk of seizures in patients with mild renal impairment ( $CrCl$  51–80 mL/min) is unknown, but

AMPYRA plasma levels in these patients may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures; estimated CrCl should be known before initiating treatment with AMPYRA.

AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.

Urinary tract infections were reported more frequently as

adverse reactions in patients receiving AMPYRA 10 mg twice daily compared to those receiving the placebo

The most common adverse events for AMPYRA in MS patients were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain.

visit: [www.AMPYRA.com](http://www.AMPYRA.com) \*

## Wheelchair Vans, Scooter Lifts and Mobility Solutions...



**MOBILITYWORKS**

MAKING THE WORLD ACCESSIBLE

12' Interior Measurement  
in 7' height with  
carried mobility  
equipment ready  
to help you

Offering a wide  
variety of new and  
used vans for  
wheelchair and  
scooter use, in  
different price  
ranges, makes and  
models.

[www.mobilityworks.com](http://www.mobilityworks.com)